Diabetes

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed why the research assessing dapagliflozin advanced from cardiorenal effects to prevention and organ protection.

Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses how the results from the phase 3 trial evaluating an investigational 2 mg dose of semaglutide could change treatment options for patients with type 2 diabetes.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed why the results of the DARE-19 trial are important to the field, especially during the COVID-19 pandemic.

Drugs to treat type 2 diabetes using SGLT2 inhibitors are relatively new, with FDA approvals only within the last decade.

Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the benefit of the investigational 2 mg dose of semaglutide injection in adults with type 2 diabetes.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed how the phase 3 DARE-19 trial was conducted to assess dapagliflozin in patients with type 2 diabetes hospitalized with COVID-19.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the findings around the safety profile of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19 during the DARE-19 trial.

Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the adverse events experienced by patients during the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide injection in adults with type 2 diabetes.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the findings around the efficacy of dapagliflozin in the DARE-19 trial assessing its efficacy and safety in patients with type 2 diabetes hospitalized with COVID-19.

Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses how the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide injection in adults with type 2 diabetes was conducted.

Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the findings around the efficacy and safety of the 2 mg dose of semaglutide for the treatment of type 2 diabetes.

The results from the first phase 3 SURPASS trials showed promising results with tirzepatide in patients with type 2 diabetes.

Novo Nordisk presented data for 2 mg dose of Ozempic at the 81st Annual Scientific Sessions of the American Diabetes Association.

This study was among the first to display the adverse relationship in younger adults, according to the letter.

The DARE-19 clinical trial explores the use of SGLT2 inhibitors for patients with hypertension, cardiovascular disease, heart failure, type 2 diabetes, or chronic kidney disease, and COVID-19.

Study presented at the American Diabetes Association (ADA) 81st Scientific Sessions shows meaningful outcomes for people with diabetes who use the FreeStyle Libre system.

Data show diabetes patients not taking medication experienced longer hospitalization and recovery from the coronavirus.

Too much bile acids can lead to damage in the cell membranes and can cause cell death and inflammation.

Initial data show that children presented with higher acuity in 2020 compared to the previous year.

Studies show that an increased life expectancy is attributable to growth in gross domestic product, increases in the average years of school, and other social factors.

Improvements in glycemic control were seen as early as 3 months after program implementation and were sustained up to a year with continued program engagement.

The objective of the study was to determine the impact of telemedicine consultations in the context of the COVID-19 pandemic on the glycemic control of patients at an endocrinology clinic.

Researchers observed improvements in total cholesterol, low-density lipoprotein, triglycerides, and serum gamma glutamyl transferase among patients both with and without diabetes.

Individuals with diabetes, and other related underlying health conditions, are being hospitalized 6 times more often and are 12 times more likely to die of COVID-19 than those without diabetes.

The researchers noted that during high-risk pregnancies, special monitoring and care throughout the pregnancy is mandatory.

Researchers noted decreases in control of blood pressure as well as non¬–high-density lipoprotein cholesterol, both of which are risk factors for diabetes.

The researchers found that the effect of fatigue from sleep disruption increased among patients with diabetes.

Continuous glucose monitors were associated with a decline in levels of HbA1c as well as reduced emergency department visits and hospitalizations for hypoglycemia.

After identifying 3 novel checkpoints involved in immunosuppression and autoimmune diseases, investigators developed recombinant proteins that could be used in this patient population.

Investigators from Monash University determined the prevalence of undiagnosed type 2 diabetes utilizing machine learning to analyze modifiable markers not included in screening guidelines.